Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
tafenoquine
technology2 mentionslast seen Oct 6, 2026
An antimicrobial compound that has produced efficacy signals in treatment-refractory babesiosis.
Relationships 3
Relationship
60 Degrees Pharmaceuticals, Inc.developstafenoquine
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 6, 202660 DEGREES PHARMACEUTICALS, INC. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
60 Degrees Pharmaceuticals, Inc. develops and commercializes new medicines for vector-borne disease
- filingSEC EDGARSep 14, 202660 DEGREES PHARMACEUTICALS, INC. 8-K: Item 8.01: Other Events
60 Degrees Pharmaceuticals, Inc. (the "Company" or "60P") submitted a Statement of Interest to the U.S. Food and Drug Administration ("FDA") requesting a Commissioner's National Priority Voucher ("CNPV") designated for an efficacy supplement to NDA 210607 for ARAKODA ® (tafenoquine) for the treatment of babesiosis